Oxysure (OXYS) Expands Medical Emergency Offerings With Six AED Brands

Oxysure (OXYS) Expands Medical Emergency Offerings With Six AED Brands

New Products Unveiled on Redesigned Website With Enhanced Sales Tools and

FRISCO, Texas, Feb. 12, 2013 (GLOBE NEWSWIRE) -- OxySure® Systems, Inc.
(OTCBB:OXYS) ("OxySure," or the "Company"), a medical device innovator of
life-saving, easy-to-use emergency oxygen solutions with its "oxygen from
powder" technology is pleased to announcethat the Company has expanded its
product offerings to include six brands of Automated External Defibrillators
(AEDs), as well as all related AED accessories. The Company has long
maintained that its flagship product, the OxySure Model 615 is an excellent
companion product for AEDs to allow pre-responders to administer oxygen,
post-resuscitation in a cardiac arrest event in public access venues as well
as in private settings.

The addition of AEDs and AED accessories from major manufacturers Cardiac
Science, Philips, Zoll, Physio Control (formerly Medtronic (NYSE: MDT)),
Defibtech and Heartsine allows OxySure to offer its customers and distribution
partners a complete solution as it relates to their cardiac arrest emergency
preparedness needs. The Company offers most AEDs by these manufacturers, as
well as related accessories such as batteries, pads, wall boxes, signage,
software, program management, compliance and training. In addition, OxySure
provides competitively priced, bundled solutions or "combo packs" comprising
both OxySure products and AED products, an option well received by customers.

There is significant clinical support for the critical need for early oxygen
administration during cardiovascular emergencies, which include cardiac
arrests. During a cardiovascular emergency, the availability of oxygen to the
heart, brain, other vital organs or injured area is either stopped or
impaired. In less than three minutes without oxygen, brain cells can begin to
die. In less than eight minutes, the heart muscle cells can begin to die. Both
of these conditions typically lead to permanent disability, since neither
brain cells nor the heart tissue is considered regenerative. In less than ten
minutes the ability to sustain life can be at risk. Even if a victim survives,
their future quality of life can be directly related to the number of minutes
that they were deprived of oxygen. Given that the response times of first
responders can be between six and 15 minutes (in the United States) from the
time 911 is called, the clinical significance and appeal of the AED/OxySure
combination becomes apparent.

According to the Morbidity and Mortality Weekly Report, each year, over 1
million Americans suffer a potentially fatal cardiac emergency - that is one
person every 34 seconds. About 460,000 of those cardiac emergencies are fatal,
death occurring before the victim can get professional medical attention.
Doctors estimate that the survival rate for people who suffer sudden cardiac
arrest outside a hospital is between 3% and 5%. Immediate action is the single
most important factor in determining the victim's survival rate. One of
OxySure's key goals is to work towards educating the public and creating
awareness regarding these issues and the need for informed, vision-forward
emergency preparedness.

The Company unveiled its new AED products on its newly redesigned website,
located at www.oxysure.com. The new website offers OxySure's customers,
distribution partners and stakeholders enhanced tools, information and

"We are excited to be able to include AEDs and AED accessories to our growing
portfolio of products," stated Julian Ross, CEO of OxySure. "Our OxySure Model
615 is considered a natural companion product to AEDs, and this move allows us
to be a single source solution to our customers and partners. "We are equally
excited to unveil our AED offerings on our newly redesigned website. Our goal
is to be a good resource to our customers and partners about AEDs, OxySure and
related products and their critical need."

OxySure's AED offerings and OxySure products can be located in the Product
Catalog section of its new website located at

About OxySure Systems, Inc.

OxySure Systems, Inc. is a Frisco, Texas-based medical technology company that
focuses on the design, manufacture and distribution of specialty respiratory
and medical solutions. The company pioneered a safe and easy to use solution
to produce medically pure (USP) oxygen from inert powders. The company owns
numerous issued patents and patents pending on this technology which makes the
provision of emergency oxygen safer, more accessible and easier to use than
traditional oxygen provision systems. OxySure's products improve access to
emergency oxygen that affects the survival, recovery and safety of individuals
in several areas of need: (1) Public and private places and settings where
medical emergencies can occur; (2) Individuals at risk for cardiac,
respiratory or general medical distress needing immediate help prior to
emergency medical care arrival; and (3) Those requiring immediate protection
and escape from exposure situations or oxygen-deficient situations in
industrial, mining, military, or other "Immediately Dangerous to Life or
Health" (IDLH) environments. www.OxySure.com

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements contained in this
release that are not historical facts, including, without limitation,
statements that relate to the Company's expectations with regard to the future
impact on the Company's results from new products in development, may be
deemed to be forward-looking statements. Words such as "expects", "intends",
"plans", "may", "could", "should", "anticipates", "likely", "believes" and
words of similar import also identify forward-looking statements. These
statements are subject to risks and uncertainties. Forward-looking statements
are based on current facts and analyses and other information that are based
on forecasts of future results, estimates of amounts not yet determined and
assumptions of management. Readers are urged not to place undue reliance on
the forward-looking statements, which speak only as of the date of this
release. Except as may be required under applicable law, we assume no
obligation to update any forward-looking statements in order to reflect any
event or circumstance that may arise after the date of this release.
Additional information on risks and other factors that may affect the business
and financial results of OxySure Systems, Inc. can be found in the filings of
OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.

Investor Relations Contact(s):

Andrew J. Barwicki, (516) 662-9461

Chris Hagerman, (208) 361-6624

Chris Castaldo, (516) 656-0217

Media Contact:
Yves Dezawy, (646) 546-5151

This information was brought to you by Cision http://www.cisionwire.com
Press spacebar to pause and continue. Press esc to stop.